• Major Adverse Cardiac Events(MACE). MACE defined as Cardiac Death, MI(Q-wave and Non Q-wave) and Rarget Vessel Revascularization (TVR) [ Time Frame: 30 Days ] [ Designated as safety issue: Yes ]
  

• Clinical Outcome: MACE [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  
• Clinical Outcome: Ischemia driven TVR [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  
• Clinical Outcome: Ischemia driven Target LesionRevascularization(TLR) [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  
• Clinical Outcome: Target Vessel Failure(TVF) [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  
• Angiographic Outcome: Device Success defined as achievment of a final residual in-stent stenosis > 30%(by QCA) using the assigned device only [ Time Frame: procedural ] [ Designated as safety issue: No ]
  
• Angiographic Outcome: Lesion Success defined as attainment of a >30% residual in-stent stenosis (by QCA) using any percutaneous method [ Time Frame: procedural ] [ Designated as safety issue: No ]
  
• Angiographic Outcome: Procedural Success without the occurrence of cardiac death, Q-wave or Non Q-wave MI or repeat revascularization of the target lesion during the hospital stay. [ Time Frame: hospital stay ] [ Designated as safety issue: Yes ]
  
• Angiographic Outcome: Angiographic in-stent and in-segment binary restenosis rate(>/= 50% diameter stenosis) [ Time Frame: at 6 months ] [ Designated as safety issue: Yes ]
  
• Angiographic Outcome: In-stent, in-segment, proximal, and distal minimum lumen diameter(MLD)) [ Time Frame: at 6 months ] [ Designated as safety issue: No ]
  
• Angiographic Outcome: Angiographic in-stent late loss, defined as the difference between the post-procedural MLD and the follow-up MLD [ Time Frame: at 6 months ] [ Designated as safety issue: No ]
  

The TriMaxx study is a prospective, multicenter, non-randomized, single-arm trial intended to demonstrate the safety and feasibility of the TriMaxx Cornary Stent System. The study will enroll 100 subjects with de novo native coronary artery lesions who meet the eligibility criteria and agree to participate in the study. Subjects will be enrolled in a sequential manner. The safety and feasibility of the TRIMAXX stent will be evaluated by comparing the MACE rate that is observed 30 days post-procedure to the MACE rate for commercially available non-drug eluting stents. Secoandry evaluations will include analysis of clinical and angiographic parameters at 6 months. All subjects will undergo assessments at 30 days and at 6 months. Additionally, all subjects will undergo a follow-up angiogram at 6 months.